Literature DB >> 14517642

Prevention and treatment of malignant hyperthermia in certified training hospitals in Japan: a questionnaire.

Hidemichi Suyama1, Masashi Kawamoto, Osafumi Yuge.   

Abstract

PURPOSE: To assess the preparedness of hospitals in Japan for cases of malignant hyperthermia (MH).
METHOD: A survey was sent to 884 training hospitals certified by the Japan Society of Anesthesiologists (JSA) in June and July 2000. Useful answers were received from 431 (48.8%) institutions.
RESULTS: For general anesthesia, inhalation anesthetics were widely used in 283 (65.7%) hospitals, and succinylcholine was the most commonly used muscle relaxant, which was used in 270 hospitals (62.5%). For patient monitoring, 422 (97.9%) hospitals used a pulse oximeter for all general anesthesia cases. A capnogram was used in 152 (35.3%) hospitals, and continuous body temperature was measured in 128 (29.7%). Two hundred and eighty-eight (66.8%) hospitals had more than six vials of dantrolene prepared for use, whereas 13 (3.0%) had none.
CONCLUSION: The results of the survey revealed that some hospitals had inadequate monitoring methods and a lack of prepared dantrolene for cases of MH under general anesthesia. We recommend that essential monitors be deployed and adequate preparations of dantrolene be maintained for effective early diagnosis and treatment of MH.

Entities:  

Year:  2002        PMID: 14517642     DOI: 10.1007/s005400200026

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  2 in total

1.  Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases.

Authors:  Takako Migita; Keiko Mukaida; Masashi Kawamoto; Masako Kobayashi; Osafumi Yuge
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

2.  [Stocks of dantrolene in anesthesia and intensive care units in Germany : Nationwide online survey with 1673 participants].

Authors:  E Pfenninger; S Heiderich; W Klingler
Journal:  Anaesthesist       Date:  2017-06-28       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.